Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

6.41
-0.3600-5.32%
Volume:437.72K
Turnover:2.83M
Market Cap:137.76M
PE:-4.00
High:6.75
Open:6.75
Low:6.31
Close:6.77
52wk High:11.00
52wk Low:3.71
Shares:21.49M
Float Shares:13.01M
Volume Ratio:1.51
T/O Rate:3.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6020
EPS(LYR):-5.6466
ROE:-102.29%
ROA:-44.23%
PB:3.68
PE(LYR):-1.14

Loading ...

Unicycive Therapeutics Inc - Nda Resubmitted After Vendor Resolves FDA Deficiencies

THOMSON REUTERS
·
Dec 29, 2025

Unicycive Therapeutics Announces Resubmission of New Drug Application (Nda) for Oxylanthanum Carbonate (Olc)

THOMSON REUTERS
·
Dec 29, 2025

Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation

Reuters
·
Dec 03, 2025

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

GlobeNewswire
·
Nov 25, 2025

Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning

TIPRANKS
·
Nov 16, 2025

Unicycive Therapeutics Doubles Stock Sale Agreement

TIPRANKS
·
Nov 15, 2025

BRIEF-Unicycive Therapeutics Increases ATM Offering To $100 Million - SEC Filing

Reuters
·
Nov 15, 2025

Unicycive Therapeutics Inc - Increases Atm Offering to $100 Mln - SEC Filing

THOMSON REUTERS
·
Nov 15, 2025

Unicycive Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate, Cash And Cash Equivalents Totaled $42.7M, With Cash Runway Into 2027

Benzinga
·
Nov 12, 2025

Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Strategy

Reuters
·
Nov 12, 2025

Unicycive Therapeutics reports Q3 results with $42.7 million cash and plans OLC NDA resubmission by year-end

Reuters
·
Nov 12, 2025

Unicycive Therapeutics Inc - on Track to Resubmit Nda for Oxylanthanum Carbonate by Year-End

THOMSON REUTERS
·
Nov 12, 2025

Unicycive Therapeutics Reports Oxylanthanum Carbonate Cuts Pill Burden in Hyperphosphatemia Trial

Reuters
·
Oct 30, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), United Therapeutics (UTHR) and Unicycive Therapeutics (UNCY)

TIPRANKS
·
Oct 30, 2025

Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Development Plans

Reuters
·
Oct 30, 2025

Guggenheim Sticks to Its Buy Rating for Unicycive Therapeutics (UNCY)

TIPRANKS
·
Oct 30, 2025

Unicycive Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 29, 2025

Unicycive Therapeutics Inc : H.c. Wainwright Raises Target Price to $22 From $9

THOMSON REUTERS
·
Oct 29, 2025

Unicycive Therapeutics to Resubmit OLC NDA After FDA Meeting

Reuters
·
Oct 28, 2025

Unicycive Therapeutics Provides Update From FDA Type a Meeting and Expects to Resubmit Olc Nda Before Year-End

THOMSON REUTERS
·
Oct 28, 2025